BATTLEFIELD WOUND INFECTION PREVENTION AND TREATMENT (BWI P&T): BARRIER COMBINATION PRODUCT DEVELOPMENT

SOL #: HT9427-26-RFI-BWI-PTSources Sought

Overview

Buyer

DEPT OF DEFENSE
Defense Health Agency (Dha)
DEFENSE HEALTH AGENCY
FORT DETRICK, MD, 21702, United States

Place of Performance

MD

NAICS

No NAICS code specified

PSC

No PSC code specified

Set Aside

No set aside specified

Timeline

1
Posted
Dec 3, 2025
2
Response Deadline
Jan 20, 2026, 7:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

The Government is conducting market research to determine whether a commercial solution can be provided to meet requirements for battlefield wound infection prevention and treatment: barrier combination product. This market research may also assist with the further development and/or refinement of the requirements.

Objective and Purpose/Scope: DHA’s OPMED WPAC has a requirement to develop, deliver, and field medical products that address battlefield wounds and subsequent bacterial and fungal infections.  The Battlefield Wound Infection Prevention and Treatment (BWI P&T) program is using a Family of Systems (FoS) approach that aims to develop multiple medical materiel solutions that are most relevant for use in austere environments where medical products may be limited and evacuation may be prolonged. 

This RFI seeks responses to the barrier combination component of this FoS only.

Although there is an emphasis on use at the point of injury, this capability will likely be used across roles

of care spanning the austere battlefield environment to hospital care settings. The barrier combination product is

expected to be one of many components of the FoS that will provide novel solutions to the DoD and commercial

market with respect to wound care and infection prevention.
 

The barrier combination product must have the following minimum essential characteristics:
 

Please refer to Attachment 3 - Minimum Essential Characteristics (MECS)

 North American Industry Classification System (NAICS) Code: Unknown

RFI Attachments: The following documents are attached to the RFI

  • Attachment 1: Technical Readiness Level (TRL) (Reference Only)
  • Attachment 2: Company & Product Information
  • Attachment 3: Minimum Essential Characteristics (MECS)

  • Response Due Date: Interested parties shall submit the RFI response electronically by 2:00pm  Eastern on January 20, 2026, via e-mail to:

Please review Attachments 1, 2, and 3 as well as RFI for BWI PT Barrier Attachment for further instructions

People

Points of Contact

Jeanette CollinsPRIMARY
Julie BurnsSECONDARY

Files

Files

Download
Download
Download
Download

Versions

Version 1Viewing
Sources Sought
Posted: Dec 3, 2025
BATTLEFIELD WOUND INFECTION PREVENTION AND TREATMENT (BWI P&T): BARRIER COMBINATION PRODUCT DEVELOPMENT | GovScope